(Q34301030)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22997445%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22997445%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22997445%20AND%20SRC:MED&resulttype=core&format=json

ESMO Guidelines Working Group

13 February 2020

5

object named as

ESMO Guidelines Working Group

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22997445%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

K Öberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22997445%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

U Knigge

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22997445%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

D Kwekkeboom

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22997445%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

1 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22997445%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22997445%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

23 Suppl 7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22997445%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

vii124-30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22997445%20AND%20SRC:MED&resulttype=core&format=json

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Imaging of neuroendocrine tumours (CT/MR/US).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Tumor markers in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Metastatic carcinoid tumor: changing patterns of care over two decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Surgery on neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. treatment of hepatic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Hepatic surgery for metastases from neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Interferon in the management of neuroendocrine GEP-tumors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS295